-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-05-15
Values as of: 2024-05-15
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the health care providers and services segment of a U.S. total market composite index. In seeking to track the performance of the S&P Health Care Services Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the health care services segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.
Company Website : www.spdrs.com
Currency: USD
Country : USA
Inception Date: 28/09/2011
Primary Benchmark: S&P Health Care Sev Sec Industry TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.35%
Management Expense Ratio: 0.35 %
N/A
N/A
| Symbol | Company Name | Allocation |
|---|---|---|
| HIMS | Hims Hers Health Inc | 2.66 % |
| HQY | HealthEquity Inc | 2.31 % |
| HCA | HCA Holdings Inc | 2.14 % |
| CHE | Chemed Corp | 2.12 % |
| EHC | Encompass Health Corp | 2.11 % |
| SGRY | Surgery Partners Inc | 2.10 % |
| DGX | Quest Diagnostics Incorporated | 2.10 % |
| UHS | Universal Health Services Inc | 2.07 % |
| AMED | Amedisys Inc | 2.07 % |
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| XLV | Health Care Select Sector SPDR.. | 0.13 % |
-0.28 (-0.19%) |
USD 40.26B |
| FHLC | Fidelity® MSCI Health Care In.. | 0.08 % |
-0.13 (-0.18%) |
USD 2.86B |
| FXH | First Trust Health Care AlphaD.. | 0.63 % |
+0.33 (+0.31%) |
USD 1.18B |
| XHE | SPDR® S&P Health Care Equipme.. | 0.35 % |
+0.24 (+0.27%) |
USD 0.21B |
| IDNA | iShares Genomics Immunology an.. | 0.00 % |
+0.08 (+0.32%) |
USD 0.14B |
| SBIO | ALPS Medical Breakthroughs ETF | 0.50 % |
-0.53 (-1.37%) |
USD 0.12B |
| HTEC | Robo Global® Healthcare Techn.. | 0.00 % |
+0.12 (+0.43%) |
USD 0.05B |
| BBP | Virtus LifeSci Biotech Product.. | 0.79 % |
-0.56 (-0.87%) |
USD 0.02B |
| BBC | Virtus LifeSci Biotech Clinica.. | 0.79 % |
-0.55 (-1.87%) |
USD 0.01B |
| IHE | iShares U.S. Pharmaceuticals E.. | 0.42 % |
-0.73 (-1.04%) |
N/A |
N/A
| Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 3.58% | 33% | F | 48% | F | ||
| Dividend Return | 0.07% | 25% | F | 2% | F | ||
| Total Return | 3.65% | 33% | F | 44% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 3.23% | 38% | F | 37% | F | ||
| Dividend Return | 0.26% | 28% | F | 2% | F | ||
| Total Return | 3.49% | 33% | F | 27% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 43.60% | 58% | F | 66% | D+ | ||
| Dividend Return | 3.68% | 50% | F | 11% | F | ||
| Total Return | 47.28% | 58% | F | 61% | D- | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 10.26% | 95% | A | 70% | C- | ||
| Dividend Return | 10.80% | 86% | B+ | 66% | D+ | ||
| Total Return | 0.54% | 53% | F | 13% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 28.43% | 24% | F | 39% | F | ||
| Risk Adjusted Return | 37.98% | 48% | F | 60% | D- | ||
| Market Capitalization | 0.10B | 19% | F | 22% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
